Business
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the
About this update from Tscan Therapeutics, Inc.
[{"type":"text","content":"WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will be presenting a Trial in Progress (TIP) poster at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held from June 2-6, 2023, at McCormick Place in Chicago, Illinois and online. Presentation Details: Title: Product characteristics and clinical trial design for T-Plex: Multiplexed, enhanced T cell receptor engineered T cell therapy for solid tumors. Presenter: Shrikanta Chattopadhyay, M.D.Abstract Number: 2554Poster Board Number: 396Session Title: Developmental Therapeutics – ImmunotherapyLocation: Hall A and On DemandTime: June 3, 2023; 8:00 am – 11:00 am CDT A copy of the poster will be added to the “Publications” section of the Company’s website at www.tscan.com once the session has concluded. About TScan Therapeutics, Inc. TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors. Contacts Heather SavelleTScan Therapeutics, Inc.VP, Investor [email protected] Joyce AllaireLifeSci Advisors, LLCManaging [email protected] \nSource: TScan Therapeutics, Inc.","length":4939,"tagName":"div"}]